Increasing Patient Acceptance and Adherence Toward Insulin

References

• Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140–149.
   PubMed Web of Science ®Google Scholar
• Handelsman Y, Bloomgarden ZT, Grunberger G, et al. American Association of Clinical Endocrinologists and American College of Endocrinology – clinical practice guidelines for developing a diabetes mellitus comprehensive care plan – 2015. Endocr Pract. 2015;21(Suppl 1):1–87.
   PubMed Web of Science ®Google Scholar
• Wright A, Burden AC, Paisey RB, et al.; U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–336.
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Glycemic targets. Sec. 5. In standards of medical care in diabetes-2016. Diabetes Care. 2016;39(Suppl. 1):S39–S46.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 2016;133:e38–e360.
   PubMed Web of Science ®Google Scholar
• Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77:126–133.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Koo YH, Shah SN. Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy. J Gen Intern Med. 2007;22:453–458.
   PubMed Web of Science ®Google Scholar
• Nichols GA, Kimes TM, Harp JB, et al. Glycemic response and attainment of A1C goals following newly initiated insulin therapy for type 2 diabetes. Diabetes Care. 2012;35:495–497.
   PubMed Web of Science ®Google Scholar
• Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753–1760.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086.
   PubMed Web of Science ®Google Scholar
• Chen HS, Wu TE, Jap TS, et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31:1927–1932.
   PubMed Web of Science ®Google Scholar
• FLAT-SUGAR Trial Investigators. Design of FLAT-SUGAR: randomized trial of prandial insulin versus prandial GLP-1 receptor agonist together with basal insulin and metformin for high-risk type 2 diabetes. Diabetes Care. 2015;38:1558–1566.
   PubMed Web of Science ®Google Scholar
• Arakaki RF, Blevins TC. Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial. Diabetes Obes Metab. 2014;16:510–518.
   PubMed Web of Science ®Google Scholar
• Buse JB, Peters A, Russell-Jones D, et al. Is insulin the most effective injectable antihyperglycaemic therapy? Diabetes Obes Metab. 2015;17:145–151.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Hajos TR, Dain MP, et al. Are patients with type 2 diabetes reluctant to start insulin therapy? An examination of the scope and underpinnings of psychological insulin resistance in a large, international population. Curr Med Res Opin. 2011;27:1169–1174.
   PubMed Web of Science ®Google Scholar
• Brod M, Alolga SL, Meneghini L. Barriers to initiating insulin in type 2 diabetes patients: development of a new patient education tool to address myths, misconceptions and clinical realities. Patient. 2014;7(4):437–450.
   PubMedGoogle Scholar
• Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: the translating research into action for diabetes insulin starts project. Diabetes Care. 2010;33:733–735.
   PubMed Web of Science ®Google Scholar
• Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Diabetes. Diabetes Care. 2015;38:1372–1382.
   PubMed Web of Science ®Google Scholar
• Mitchell VD, Porter K, Beatty SJ. Administration technique and storage of disposable insulin pens reported by patients with diabetes. Diabetes Educator. 2012;38:651–658.
   PubMed Web of Science ®Google Scholar
• Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648–659.
   PubMed Web of Science ®Google Scholar
• US FDA. Drugs@FDA; [cited 2016 Jan 12]. Available from: http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA
   Google Scholar
• Yki-Jarvinen H, Bergenstal R, Ziemen M, et al.; EDITION-2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37:3235–3243.
   PubMed Web of Science ®Google Scholar
• Rolla A. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 2008;121(Supp l):S9–S19.
   PubMed Web of Science ®Google Scholar
• Rave K, Heise T, Heinemann L, et al. Inhaled technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. J Diabetes Sci Technol. 2008;2:205–212.
   PubMedGoogle Scholar
• Rosenstock J, Franco D, Korpachev V, et al.; Affinity 2 Study Group. Inhaled technosphere insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents. Diabetes Care. 2015;38:2274–2281.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Cefalu WT, Hollander PA, et al. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. Diabetes Care. 2008;31:2177–2182.
   PubMed Web of Science ®Google Scholar
• Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care. 2005;28:1240–1244.
   PubMed Web of Science ®Google Scholar
• Eby EL, Wang P, Curtis BH, et al. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis. J Med Econ. 2013;16(4):529–538.
   PubMedGoogle Scholar
• Hirsch IB. Insulin analogues. N Engl J Med. 2005;352:174–183.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Ligthelm R, Christiansen JS, et al. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab. 2007;9:630–639.
   PubMed Web of Science ®Google Scholar
• Diamant M, Nauck MA, Shaginian R, et al.; 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care. 2014;37:2763–2773.
   PubMed Web of Science ®Google Scholar
• Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol. 2012;11:142.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Jelaska A, Zeller C, et al.; EMPA-REG BASAL™ trial investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015;17:936–948.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
   PubMed Web of Science ®Google Scholar
• Frandsen CS, Madsbad S. Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with type 2 diabetes: a review. Diabet Med. 2014;31:1293–1300.
   PubMed Web of Science ®Google Scholar
• Norman J, Norman JJ, Brown MR, et al. Faster pharmacokinetics and increased patient acceptance of intradermal insulin delivery using a single hollow microneedle in children and adolescents with diabetes. Pediatr Diabetes. 2013;14:459–465.
   PubMed Web of Science ®Google Scholar
• McVey E, Hirsch L, Sutter DE, et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. J Diabetes Sci Technol. 2012;6:743–754.
   PubMedGoogle Scholar
• Perez-Nieves M, Jiang D, Eby E. Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011). Curr Med Res Opin. 2015;31:891–899.
   PubMed Web of Science ®Google Scholar
• Kimball ES, Aagren M. Coverage of insulin delivery devices and basal insulin analogs by US managed care organizations. J Med Econ. 2011;14:720–728.
   PubMedGoogle Scholar
• Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther. 2008;10:247–256.
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, et al. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365:2002–2012.
   PubMed Web of Science ®Google Scholar
• Eby EL, Boye KS, Lage MJ. Mealtime insulin administration: pens vs vials. Am J Pharm Benefits. 2013;5(6): e159–e167.
   PubMedGoogle Scholar
• Selam JL. Evolution of diabetes insulin delivery devices. J Diabetes Sci Technol. 2010;4:505–513.
   PubMedGoogle Scholar
• Asakura T. Comparison of clinically relevant technical attributes of five insulin injection pens. J Diabetes Sci Technol. 2011;5:1203–1209.
   PubMedGoogle Scholar
• Grunberger G, Bailey TS, Cohen AJ, et al.; AACE Insulin Pump Management Task Force. Statement by the American Association of clinical endocrinologists consensus panel on insulin pump management. Endocr Pract. 2010;16:746–762.
   PubMed Web of Science ®Google Scholar
• Veiseh O, Langer R. Diabetes: a smart insulin patch. Nature. 2015;524:39–40.
   PubMed Web of Science ®Google Scholar
• Yu J, Zhang Y, Ye Y, et al. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery. Proc Natl Acad Sci U S A. 2015;112:8260–8265.
   PubMed Web of Science ®Google Scholar